Join the Lung Cancer group to help and get support from people like you.
Lung Cancer News (Page 5)
Related terms: Cancer, Bronchogenic Carcinoma, Cancer, Lung
Most Cancer Screens Won't Extend Lives, But Reasons to Keep Screening Remain
MONDAY, Aug. 28, 2023 – While new research suggests cancer screenings are not extending lives for the most part, the study's authors stressed that there are still good reasons why people should...
Cancer Screening Has Provided Significant Value to U.S. Population
TUESDAY, Aug. 22, 2023 – Cancer screening has provided significant value to the U.S. population, and improved adherence would add more value, according to a study published online Aug. 7 in BMC...
Fit When Young? You May Have a Lower Risk of 9 Cancers as You Age
WEDNESDAY, Aug. 16, 2023 – Having good fitness while young can really pay off when it comes to cancer risk later in life. New research found that cardiorespiratory fitness – the ability to do...
Stress, Depression Won't Raise Your Odds for Cancer: Study
WEDNESDAY, Aug. 9, 2023 – A large new study challenges the long-held idea that depression makes people more vulnerable to cancer, finding no association between the mental health condition and most...
Plasma ctDNA Genotyping Can Accelerate Time to Treatment for NSCLC
FRIDAY, July 28, 2023 – For patients with suspected advanced non-small cell lung cancer (NSCLC), plasma circulating tumor (ct)DNA genotyping before tissue diagnosis is associated with accelerated...
FDA Approves Tabrecta (capmatinib) for Metastatic Non-Small Cell Lung Cancer with METex14
EAST HANOVER, N.J., May 6, 2020 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib, formerly INC280), an oral MET inhibitor for adul...
FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer
South San Francisco, CA – March 18, 2019 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq...
FDA Approves Keytruda (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
KENILWORTH, N.J.--(BUSINESS WIRE) October 30, 2018 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Lorbrena (lorlatinib) for Previously-Treated ALK-Positive Metastatic Non-Small Cell Lung Cancer
November 2, 2018 Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Lorbrena [lor-BREN-ah] (lorlatinib), a third-generation anaplastic lymphoma...
FDA Approves Vizimpro (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
September 27, 2018 - Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Vizimpro [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line...
FDA Approves Opdivo (nivolumab) for Certain Patients with Previously Treated Small Cell Lung Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--August 17, 2018 – Bristol-Myers Squibb Company (NYSE:BMY) today announced that Opdivo (nivolumab) received approval from the U.S. Food and Drug Administration (FDA)...
FDA Approves Tagrisso (osimertinib) as First-Line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer
18 April 2018 – AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell...
FDA Approves Alecensa (alectinib) as First-Line Treatment for ALK-Positive Metastatic Non-Small Cell Lung Cancer
South San Francisco, CA – November 6, 2017 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved the...
FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin
September 14, 2017 – The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is...
FDA Approves Merck’s Keytruda (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer
KENILWORTH, N.J.--(BUSINESS WIRE) October 24, 2016 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
Ask a question
To post your own question to this support group, sign in or create an account.